Trivalent Tasmania influenza vaccine - Sanofi
Alternative Names: Trivalent-Tasmania influenza vaccineLatest Information Update: 08 Oct 2024
Price :
$50 *
At a glance
- Originator Sanofi
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 12 Aug 2024 Phase-I clinical trials in Influenza virus infections (Prevention) in Australia (IM) (NCT06507553)
- 18 Jul 2024 Sanofi plans a phase I trial for Influenza virus infections (Prevention) in Australia (IM, Injection) in August 2024 (NCT06507553)
- 18 Jul 2024 Preclinical trials in Influenza virus infections (Prevention) in Australia (IM) prior to July 2024